{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:11Z","timestamp":1792067771486,"version":"4.4.0"},"reference-count":119,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic mutations that are known or suspected to be oncogenic in the malignant cells. The genetic risk stratification of MDSs has evolved substantially with the introduction of the clinical molecular international prognostic scoring system, which establishes next-generation sequencing at diagnosis as a standard of care. Furthermore, the International Consensus Classification of myeloid neoplasms and acute leukemias has refined the MDS diagnostic criteria with the introduction of a new MDS\/acute myeloid leukemia category. Monitoring measurable residual disease (MRD) has historically been used to define remission status, improve relapse prediction, and determine the efficacy of antileukemic drugs in patients with acute and chronic leukemias. However, in contrast to leukemias, assessment of MRD, including tracking of patient-specific mutations, has not yet been formally defined as a biomarker for MDS. This article summarizes current evidence and challenges and provides a conceptual framework for incorporating MRD into the treatment of MDS and future clinical trials.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010098","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T18:15:08Z","timestamp":1685729708000},"page":"4381-4394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6672-4592","authenticated-orcid":false,"given":"Eduard","family":"Schulz","sequence":"first","affiliation":[{"name":"1Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"2Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-9969","authenticated-orcid":false,"given":"Peter D.","family":"Aplan","sequence":"additional","affiliation":[{"name":"1Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"2Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Z.","family":"Pavletic","sequence":"additional","affiliation":[{"name":"1Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"2Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"12","key":"2023082114543640700_bib1","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"2023082114543640700_bib2","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"26","key":"2023082114543640700_bib3","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023082114543640700_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023082114543640700_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023082114543640700_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2023082114543640700_bib7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023082114543640700_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/bjh.17838","article-title":"Meaningful response criteria for myelodysplastic syndromes","volume":"196","author":"Kim","year":"2022","journal-title":"Br J Haematol"},{"issue":"17","key":"2023082114543640700_bib9","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2023082114543640700_bib10","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD working party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"issue":"5","key":"2023082114543640700_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023082114543640700_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cyto.b.22108","article-title":"Multiparameter flow cytometry in the evaluation of myelodysplasia: analytical issues: recommendations from the European LeukemiaNet\/International Myelodysplastic Syndrome Flow Cytometry Working Group","volume":"104","author":"Porwit","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2023082114543640700_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cyto.b.22105","article-title":"Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS Flow Working Group","volume":"104","author":"Kern","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2023082114543640700_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/bloodadvances.2022008141","article-title":"Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia","volume":"7","author":"Simoes","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023082114543640700_bib15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41375-023-01811-5","article-title":"Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression","volume":"37","author":"van Spronsen","year":"2023","journal-title":"Leukemia"},{"issue":"32","key":"2023082114543640700_bib16","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023082114543640700_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ajcp\/aqac083","article-title":"Abnormal CD13\/HLA-DR expression pattern on myeloblasts predicts development of myeloid neoplasia in patients with clonal cytopenia of undetermined significance","volume":"158","author":"Dragan","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2023082114543640700_bib18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41375-022-01657-3","article-title":"Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome","volume":"36","author":"Janssen","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2023082114543640700_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2017.285","article-title":"Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse","volume":"32","author":"Boddu","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"2023082114543640700_bib20","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2023082114543640700_bib21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023082114543640700_bib22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/bloodadvances.2020003195","article-title":"Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial","volume":"5","author":"Simoes","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2023082114543640700_bib23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023082114543640700_bib24","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2023082114543640700_bib25","first-page":"3666","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood\u00a0Adv."},{"issue":"5","key":"2023082114543640700_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.leukres.2014.02.001","article-title":"Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"38","author":"Bernal","year":"2014","journal-title":"Leuk Res"},{"issue":"7","key":"2023082114543640700_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2016.03.029","article-title":"Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome","volume":"22","author":"Festuccia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023082114543640700_bib28","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-016-2706-y","article-title":"Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"95","author":"Mo","year":"2016","journal-title":"Ann Hematol"},{"key":"2023082114543640700_bib29","doi-asserted-by":"crossref","first-page":"700234","DOI":"10.3389\/fonc.2021.700234","article-title":"The prognostic value of early detection of minimal residual disease as defined by flow cytometry and gene mutation clearance for myelodysplastic syndrome patients after myeloablative allogeneic hematopoietic stem-cell transplantation","volume":"11","author":"Hou","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"2023082114543640700_bib30","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2023082114543640700_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2023082114543640700_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2023082114543640700_bib33","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"issue":"1","key":"2023082114543640700_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41467-017-01590-5","article-title":"The genomic landscape of pediatric myelodysplastic syndromes","volume":"8","author":"Schwartz","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"2023082114543640700_bib35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40291-022-00581-7","article-title":"Clinical utility of implementing a frontline NGS-Based DNA and RNA fusion panel test for patients with suspected myeloid malignancies","volume":"26","author":"Bhai","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"11","key":"2023082114543640700_bib36","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by duplex sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"issue":"7","key":"2023082114543640700_bib37","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/leu.2015.17","article-title":"Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing","volume":"29","author":"Young","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2023082114543640700_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/PPO.0000000000000572","article-title":"Measurable residual disease assessment as a surrogate marker in new drug development in acute myeloid leukemia","volume":"28","author":"Gui","year":"2022","journal-title":"Cancer J"},{"issue":"2","key":"2023082114543640700_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet"},{"issue":"8","key":"2023082114543640700_bib40","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.2019004397","article-title":"Preleukemic and leukemic evolution at the stem cell level","volume":"137","author":"Stauber","year":"2021","journal-title":"Blood"},{"issue":"26","key":"2023082114543640700_bib41","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023082114543640700_bib42","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2023082114543640700_bib43","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2023082114543640700_bib44","doi-asserted-by":"crossref","first-page":"e0224097","DOI":"10.1371\/journal.pone.0224097","article-title":"Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing","volume":"14","author":"Balagopal","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"2023082114543640700_bib45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41375-018-0284-9","article-title":"Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes","volume":"33","author":"Falconi","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"2023082114543640700_bib46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow","volume":"137","author":"Godwin","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023082114543640700_bib47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.17449","article-title":"Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse","volume":"195","author":"Skou","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"2023082114543640700_bib48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2016-10-745273","article-title":"Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy","volume":"129","author":"Duncavage","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2023082114543640700_bib49","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","article-title":"Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS","volume":"133","author":"Nakamura","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023082114543640700_bib50","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1182\/blood-2022-169413","article-title":"Cell-free DNA (cfDNA)-based measurable residual disease (MRD) detection as a predictor of relapse post-allogeneic blood or marrow transplant (alloBMT) in patients with myeloid malignancies","volume":"140","author":"Pasca","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023082114543640700_bib51","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2023082114543640700_bib52","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023082114543640700_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2023082114543640700_bib54","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41375-020-0869-y","article-title":"Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders","volume":"34","author":"Midic","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"2023082114543640700_bib55","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood.2020010163","article-title":"CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease","volume":"138","author":"Hecker","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023082114543640700_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2023082114543640700_bib57","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","article-title":"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes","volume":"128","author":"Greenberg","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2023082114543640700_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2643-3230.BCD-21-0155","article-title":"Convergent clonal evolution of signaling gene mutations is a hallmark of myelodysplastic syndrome progression","volume":"3","author":"Menssen","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2023082114543640700_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2643-3230.BCD-21-0128","article-title":"Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia","volume":"3","author":"Guess","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2023082114543640700_bib60","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"2023082114543640700_bib61","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-021-01411-9","article-title":"Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis","volume":"27","author":"Saiki","year":"2021","journal-title":"Nat Med"},{"issue":"14","key":"2023082114543640700_bib62","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood.2021010815","article-title":"Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia","volume":"138","author":"Tsaknakis","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2023082114543640700_bib63","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Galli","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2023082114543640700_bib64","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023082114543640700_bib65","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"14","key":"2023082114543640700_bib66","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023082114543640700_bib67","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41409-022-01567-z","article-title":"Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation","volume":"57","author":"Soerensen","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2023082114543640700_bib68","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023082114543640700_bib69","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-014-2191-0","article-title":"Preexisting TP53 mutation in therapy-related acute myeloid leukemia","volume":"94","author":"Schulz","year":"2015","journal-title":"Ann Hematol"},{"issue":"5","key":"2023082114543640700_bib70","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2023082114543640700_bib71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/PO.20.00355","article-title":"Impact of conditioning intensity and genomics on relapse after allogeneic transplantation for patients with myelodysplastic syndrome","volume":"5","author":"Dillon","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"2023082114543640700_bib72","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2023082114543640700_bib73","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023082114543640700_bib74","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023082114543640700_bib75","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2023082114543640700_bib76","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/bloodadvances.2021006233","article-title":"Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML","volume":"6","author":"Stasik","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2023082114543640700_bib77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023082114543640700_bib78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023082114543640700_bib79","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3324\/haematol.2015.135467","article-title":"Droplet digital polymerase chain reaction for DNMT3A and IDH1\/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Brambati","year":"2016","journal-title":"Haematologica"},{"issue":"7834","key":"2023082114543640700_bib80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"4","key":"2023082114543640700_bib81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/2643-3230.BCD-21-0046","article-title":"Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from non-malignant clonal hematopoiesis","volume":"2","author":"Dillon","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2023082114543640700_bib82","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2023082114543640700_bib83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023082114543640700_bib84","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"},{"issue":"14","key":"2023082114543640700_bib85","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/bloodadvances.2022009564","article-title":"Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms","volume":"7","author":"Nannya","year":"2023","journal-title":"Blood Adv"},{"key":"2023082114543640700_bib86","author":"Food and Drug Administration","year":"2018"},{"issue":"11","key":"2023082114543640700_bib87","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"2023082114543640700_bib88","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-018-0126-z","article-title":"The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)","volume":"8","author":"Sekeres","year":"2018","journal-title":"Blood Cancer J"},{"issue":"15","key":"2023082114543640700_bib89","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"Jadersten","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023082114543640700_bib90","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2016.111","article-title":"Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the German MDS Study Group (GMDS)","volume":"30","author":"Mossner","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2023082114543640700_bib91","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.3324\/haematol.2017.181404","article-title":"Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide","volume":"103","author":"Lode","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2023082114543640700_bib92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger\u2606)","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"2023082114543640700_bib93","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2016.282","article-title":"Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy","volume":"31","author":"Uy","year":"2017","journal-title":"Leukemia"},{"key":"2023082114543640700_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00119","article-title":"Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence","volume":"3","author":"Nazha","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"2023082114543640700_bib95","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023082114543640700_bib96","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2023082114543640700_bib97","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023082114543640700_bib98","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023082114543640700_bib99","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"15","key":"2023082114543640700_bib100","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023082114543640700_bib101","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3324\/haematol.2021.280153","article-title":"Decitabine salvage for TP53-mutated, relapsed\/refractory acute myeloid leukemia after cytotoxic induction therapy","volume":"107","author":"Ferraro","year":"2022","journal-title":"Haematologica"},{"issue":"30","key":"2023082114543640700_bib102","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kroger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2023082114543640700_bib103","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023082114543640700_bib104","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"25","key":"2023082114543640700_bib105","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2023082114543640700_bib106","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023082114543640700_bib107","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.24306","article-title":"Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations","volume":"91","author":"Hamilton","year":"2016","journal-title":"Am J Hematol"},{"issue":"17","key":"2023082114543640700_bib108","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023082114543640700_bib109","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023082114543640700_bib110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00277-017-3027-5","article-title":"Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation","volume":"96","author":"Heuser","year":"2017","journal-title":"Ann Hematol"},{"issue":"11","key":"2023082114543640700_bib111","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.clml.2017.06.003","article-title":"TP53 and IDH2 somatic mutations are associated with inferior overall survival after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome","volume":"17","author":"Kharfan-Dabaja","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2023082114543640700_bib112","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.21.00603","article-title":"Reply to G. Gui et\u00a0al","volume":"39","author":"Craddock","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023082114543640700_bib113","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","article-title":"Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"2023082114543640700_bib114","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023082114543640700_bib115","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2023082114543640700_bib116","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3324\/haematol.2016.162909","article-title":"Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Woo","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"2023082114543640700_bib117","doi-asserted-by":"crossref","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2023082114543640700_bib118","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ajh.24650","article-title":"Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents","volume":"92","author":"Jabbour","year":"2017","journal-title":"Am J Hematol"},{"issue":"13","key":"2023082114543640700_bib119","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cncr.34762","article-title":"Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: a multicenter, retrospective cohort study","volume":"129","author":"Ma","year":"2023","journal-title":"Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4381\/2072881\/blooda_adv-2023-010098-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4381\/2072881\/blooda_adv-2023-010098-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T16:29:06Z","timestamp":1702571346000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4381\/496148\/Moving-toward-a-conceptualization-of-measurable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":119,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010098","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}